Coronavirus Vaccine Efficacy Rate Set At 50% Because That’s What US FDA ‘Could Tolerate’

 
• By Derrick Gingery
Accelerated approval may not be appropriate for early coronavirus vaccine candidates, CBER Director Peter Marks said in an up-close look at FDA’s decision-making as it developed its guidance. • Source: screenshot

More from Vaccines

More from Pink Sheet